Gene therapy could free Beta-Thalassemia patients from lifelong transfusions
NCT ID NCT06308159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a gene therapy for people with severe beta-thalassemia who need regular blood transfusions. The treatment modifies the patient's own blood stem cells to produce healthy hemoglobin, aiming to reduce or eliminate the need for transfusions. Six participants are being monitored for safety and effectiveness over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Kunming, Yunnan, 650100, China
-
Kunming Hope of Health Hospital
Kunming, Yunnan, 650200, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy aims to free Beta-Thalassemia patients from lifelong transfusions
- How does a blood disorder drug perform in everyday practice?
- Newborn screening study aims to catch rare diseases at birth
- New stem cell transplant aims to ease severe blood disorders
- Gene-Editing breakthrough offers hope for blood disorder patients
- New stem cell transplant could help sickle cell patients without a perfect donor match